Management of Primary Sjögren's Syndrome with Secondary Systemic Amyloidosis

Introduction to Management

The European League Against Rheumatism (EULAR) recommends a tailored approach focusing on organ-specific severity using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) definitions, with systemic therapies reserved for active systemic disease and amyloid-affected organs 1, 2, 3

The EULAR recommends evaluating disease activity using validated tools such as the ESSDAI to guide therapeutic decisions and monitor response 3, 4
Monitor for development of lymphoma, which occurs in 2-5% of Sjögren's patients and may be associated with amyloidosis 3, 4

The EULAR suggests glucocorticoids should be used at the minimum dose and length of time necessary to control active systemic disease 2, 3, 4
Immunosuppressive agents (leflunomide, methotrexate, azathioprine, mycophenolate, cyclophosphamide) should be used as glucocorticoid-sparing agents in patients requiring long-term therapy 1, 2, 4
B-cell targeted therapies, particularly rituximab, may be considered in patients with severe, refractory systemic disease including those with amyloidosis 2, 3

For fatigue and musculoskeletal pain, evaluate for contributing conditions and use analgesics according to pain severity following the WHO pain ladder 4
Hydroxychloroquine may be considered for fatigue and arthralgias, though evidence for efficacy is limited 4
For chronic, non-inflammatory pain, physical activity and aerobic exercise are recommended rather than medications 1, 4
Avoid repeated use of NSAIDs or opioids for chronic pain management 1

A reduction of ≥3 points in the global ESSDAI score is recommended as definition of therapeutic response in systemic Sjögren's syndrome 1, 2